Table 1.
COVID-19 symptoms, severity, treatments, outcomes, and complications among older adults with cancer, stratified by geriatric risk index
| Standard-risk patients | Intermediate-risk patients | High-risk patients | |||
|---|---|---|---|---|---|
| Outcomes | |||||
| Hospitalised | 1122/2365 (47·4%) | 1524/2217 (68·7%) | 925/1088 (85·0%) | ||
| Without oxygen requirement | 351/2358 (14·9%) | 406/2205 (18·4%) | 221/1080 (20·5%) | ||
| With oxygen requirement | 764/2358 (32·4%) | 1108/2205 (50·2%) | 699/1080 (64·7%) | ||
| Admitted to intensive care unit | 319/2350 (13·6%) | 478/2193 (21·8%) | 249/1060 (23·5%) | ||
| Received mechanical ventilation | 211/2357 (9·0%) | 305/2204 (13·8%) | 128/1076 (11·9%) | ||
| Died within 30 days | 161/2365 (6·8%) | 409/2216 (18·5%) | 350/1089 (32·1%) | ||
| Died during follow-up | 234/2365 (9·9%) | 523/2217 (23·6%) | 438/1089 (40·2%) | ||
| Presentation of infection* | |||||
| No symptoms | 332/2365 (14·0%) | 307/2217 (13·8%) | 125/1089 (11·5%) | ||
| Typical | 1926/2365 (81·4%) | 1788/2217 (80·6%) | 865/1089 (79·4%) | ||
| Atypical | 107/2365 (4·5%) | 122/2217 (5·5%) | 99/1089 (9·1%) | ||
| Severity at presentation† | |||||
| Mild | 1431/2360 (60·6%) | 958/2210 (43·3%) | 282/1084 (26·0%) | ||
| Moderate | 736/2360 (31·2%) | 964/2210 (43·6%) | 625/1084 (57·7%) | ||
| Severe | 193/2360 (8·2%) | 288/2210 (13·0%) | 177/1084 (16·3%) | ||
| Anti-COVID-19 treatments | |||||
| Remdesivir | 283/2268 (12·5%) | 362/2144 (16·9%) | 165/1063 (15·5%) | ||
| Hydroxychloroquine | 306/2268 (13·5%) | 384/2144 (17·9%) | 226/1063 (21·3%) | ||
| Corticosteroids | 471/2268 (20·8%) | 587/2144 (27·4%) | 270/1063 (25·4%) | ||
| Other | 554/2268 (24·4%) | 595/2144 (27·8%) | 296/1063 (27·8%) | ||
| None | 1339/2268 (59·0%) | 1059/2144 (49·4%) | 488/1063 (45·9%) | ||
| Complications | |||||
| Cardiovascular | 401/2354 (17%) | 649/2201 (29·5%) | 430/1079 (39·9%) | ||
| Pulmonary | 761/2353 (32·3%) | 1052/2207 (47·7%) | 663/1081 (61·3%) | ||
| Gastrointestinal | 88/2347 (3·7%) | 104/2195 (4·7%) | 49/1074 (4·6%) | ||
| Systemic | 293/2349 (12·5%) | 513/2199 (23·3%) | 309/1076 (28·7%) | ||
| Acute kidney injury | 268/2349 (11·4%) | 522/2199 (23·7%) | 382/1079 (35·4%) | ||
| Cancer therapy modification‡ | 290/640 (45·3%) | 207/462 (44·8%) | 77/157 (49·0%) | ||
| Delayed | 273/640 (42·7%) | 189/462 (40·9%) | 71/157 (45·2%) | ||
| Stopped | <5/640 (<1%) | 8/462 (1·7%) | <5/157 (<3%) | ||
| Continued at a lower dose | <5/640 (<1%) | <5/462 (<1%) | <5/157 (<3%) | ||
Data are n/N (%). Cells with less than five patients were masked (ie, <5) to minimise the risk of re-identification as per CCC19 policy. Number of patients does not include those with missing data. CCC19=COVID-19 and Cancer Consortium.
No symptoms: none of the following typical or atypical symptoms reported; typical: at least one typical symptom reported (fever [subjective, >100·4°F, or >38°C], cough, dyspnoea, myalgia, arthralgia, headache, anosmia, ageusia, sore throat, rhinorrhoea, nausea, vomiting, diarrhoea, or abdominal pain); atypical: only atypical symptoms reported (fatigue, altered mental state, abdominal discomfort, conjunctivitis, or all other symptoms).
Mild: no hospitalisation indicated; moderate: hospitalisation indicated, despite whether it occurred; severe: intensive care unit admission indicated, despite whether it occurred.
Among patients receiving anticancer therapy within 3 months before a COVID-19 diagnosis. Subsequent cancer therapy modification is only collected on the follow-up forms, such that patients with only baseline forms filled would not have this information.